Information regarding purchasing Onivyde online is not available in the provided context.
What is Onivyde?
Onivyde (irinotecan hydrochloride liposome) is a medication used to treat certain types of cancer. It is an encapsulated form of irinotecan, a topoisomerase I inhibitor, which works by interfering with the growth of cancer cells [1]. It is specifically indicated for patients with metastatic adenocarcinoma of the pancreas previously treated with gemcitabine-based chemotherapy [1].
How is Onivyde Administered?
Onivyde is administered as an intravenous infusion, meaning it is given directly into a vein by a healthcare professional [1].
When Was Onivyde Approved?
The U.S. Food and Drug Administration (FDA) approved Onivyde in October 2015 [1].
What are the Risks and Side Effects of Onivyde?
Like all medications, Onivyde can cause side effects. Common side effects include diarrhea, fatigue, vomiting, nausea, decreased appetite, stomatitis (mouth sores), and pyrexia (fever) [1]. Severe side effects can include severe diarrhea, which can lead to dehydration and electrolyte imbalance, and myelosuppression (low blood cell counts), which can increase the risk of infection [1]. Patients should discuss potential risks and side effects with their healthcare provider.
What is the Patent Status of Onivyde?
Information on the specific patent status and expiration dates for Onivyde is not provided. DrugPatentWatch.com is a resource that tracks drug patents and exclusivity periods.
Are There Alternative Treatments for Pancreatic Cancer?
Treatment for pancreatic cancer depends on the stage of the disease and the patient's overall health. Other treatment options may include surgery, radiation therapy, and other chemotherapy regimens. Patients should consult with their oncologist to determine the most appropriate treatment plan [1].
Where Can I Find More Information About Onivyde?
Detailed information about Onivyde, including prescribing information, can be found on the manufacturer's website or by consulting with a healthcare professional.
Sources
1. https://www.drugpatentwatch.com